Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

02 July 2018 Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Second approval in Japan for AstraZeneca and MSD’s Lynparza AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer

02 July 2018 Imfinzi is the only immunotherapy approved for unresectable Stage III NSCLC Approval is based on the Phase III PACIFIC trial AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of

LOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia

LOKELMA provides a rapid and sustained treatment for hyperkalemia, a condition with high unmet need1,2,3,4 May 18, 2018 WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved LOKELMATM (sodium zirconium cyclosilicate), formerly ZS-9, for

AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease

11 May 2018 GALATHEA Phase III trial did not meet the primary endpoint of a statistically-significant reduction of exacerbations in patients with COPD Second Phase III trial TERRANOVA is ongoing with results expected later this quarter AstraZeneca and MedImmune, its

Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer

8 May 2018 Women with platinum-sensitive ovarian cancer now have access to maintenance therapy with AstraZeneca and MSD’s Lynparza, regardless of BRCA status Lynparza has over five years’ efficacy and safety follow-up data New formulation reduces dosing to two tablets twice

AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets

7 May 2018 AstraZeneca to receive upfront payment and future payments AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international

Tagrisso receives positive EU CHMP opinion for 1st-line treatment of EGFR-mutated non-small cell lung cancer

Recommendation based on FLAURA trial data showing unprecedented median progression-free survival of 18.9 months for Tagrisso versus 10.2 months compared with current standard of care The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has

AstraZeneca reports results from the ARCTIC trial in third-line non-small cell lung cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments. This randomised, open-label,

US FDA approves Tagrisso as 1st-line treatment for EGFR-mutated non-small cell lung cancer

1st-line use of Tagrisso offers potential new standard of care Tagrisso delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care AstraZeneca today announced that the US Food and Drug Administration (FDA) has

Updated overall survival data for Lynparza in BRCA-mutated HER2-negative metastatic breast cancer presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial showing the final overall survival (OS) results for Lynparza (olaparib) in metastatic breast cancer at